Protocol Ledger

NCT05287126 · Phase II · RECRUITING

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Interventional Phase II clinical trial protocol NCT05287126 sponsored by Pfizer in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-16 Enrollment: 36 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05287126
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)36 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05287126
Protocol FieldVerified Registry Value
NCT IdentifierNCT05287126
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment36 participants (ESTIMATED)
Registered Start Date2022-12-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI